Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

Plasmablastic Lymphoma - Experience with Infusional EPOCH Chemotherapy from India

Jayachandran PK, MD MRCP, DM, Arun Kumar Rajan, MD DM, Nikita Mehra, MD DM, Gangothri Selvarajan, MD DM, Joshi Archit Girishchandra, MD DM, Parathan Karunakaran, MD DM, Manikandan Dhanushkodi, MD DM, Venkatraman Radhakrishnan, MD DM, Krishnarathinam Kannan, MD DM, Trivadi S Ganesan, MD FRCP, PhD, Tenali Gnana Sagar, MD DM

Blood (2019) 134 (Supplement_1): 5351.

https://doi.org/10.1182/blood-2019-127158

Published: 2019

Journal Articles

Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Colombe Saillard, MD, Frederique Rousseau, Maud Cecile, Cecile Braticevic, Anne Etienne, Jerome Rey, Evelyne D'Incan, Christophe Zemmour, Norbert Vey, MD PhD, Aude Charbonnier

Blood (2018) 132 (Supplement 1): 2671.

https://doi.org/10.1182/blood-2018-99-116400

Published: 2018

Journal Articles

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Julie A. Wolfson, MD MS, Smita Bhatia, MD MPH, Jill Ginsberg, MD, Laura Becker, MS, David Bernstein, Henry (Joe) Henk, PhD, Gary H. Lyman, MD MPH, FRCP, Paul Nathan, MD, Diane Puccetti, MD, Jennifer J. Wilkes, MD, Lena E. Winestone, MD, Kelly Kenzik, PhD

Blood (2018) 132 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2018-99-110649

Published: 2018

Journal Articles

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Blood (2018) 132 (Supplement 1): 572.

https://doi.org/10.1182/blood-2018-99-111901

Published: 2018

Journal Articles

Influence of Pomalidomide and Lenalidomide on Total Cost of Care for Medicare Beneficiaries with Multiple Myeloma Under the Oncology Care Model (OCM)

Haley Hines Theroux, Luis M Isola, MD, Mark Liu, Alaysia Williams, MHA

Blood (2018) 132 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2018-99-116657

Published: 2018

Journal Articles

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

Andrea Sitlinger, MD, Rishi Sachdev, David Anderson, BS/MS, S. Yousuf Zafar, MD MHS

Blood (2017) 130 (Supplement 1): 4680.

https://doi.org/10.1182/blood.V130.Suppl_1.4680.4680

Published: 2017

Journal Articles

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Betty Gration, MBBS, Ana Duran, MD, Naheed Mir, BSc, FRCP, FRCPath, Lisa Yuen, MPharm, PgDip, IP, Marcus Warner, MPharm, PG Dip GPP, Karen Stanley, RGN, MSc Advanced Practice, Jessica Brady, MBBCh, FRCR, George Mikhaeel, MB BCh, MSc, FRCR, Paul A Fields, MD PhD, David Wrench, MA, MBBChir, FRCPath, PhD

Blood (2017) 130 (Supplement 1): 4133.

https://doi.org/10.1182/blood.V130.Suppl_1.4133.4133

Published: 2017

Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD

Blood (2016) 128 (22): 1795.

https://doi.org/10.1182/blood.V128.22.1795.1795

Published: 2016

Journal Articles

Treatment of Primary Cutaneous Marginal Zone B-Cell Lymphomas with Intralesional Rituximab

Eva Domingo Domenech, MD, Queralt Salas, MD, Octavio Servitje, MD PhD, Fina Climent, MD PhD, Helena Pomares, Ana Lucas, MD, Carmen Aguilera, Mrs, Alessandra Comai, Santiago Mercadal, MD, Eva Gonzalez Barca, PhD, Anna Sureda, MD PhD

Blood (2016) 128 (22): 1796.

https://doi.org/10.1182/blood.V128.22.1796.1796

Published: 2016

Journal Articles

Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era

John L Reagan, MD, Thomas Ollila, MD, Patrycja M Dubielecka, PhD, Adam J Olszewski, MD

Blood (2016) 128 (22): 1994.

https://doi.org/10.1182/blood.V128.22.1994.1994

Published: 2016

Journal Articles

Association of Medicare Part D Coverage and Low-Income Subsidies with Use of Novel Oral Agents in Multiple Myeloma

Adam J Olszewski, MD, Charles B Eaton, MD MS, Amal N Trivedi, MD MPH

Blood (2016) 128 (22): 686.

https://doi.org/10.1182/blood.V128.22.686.686

Published: 2016

Journal Articles

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Eva Domingo-Domenech, MD, Queralt Salas, MD, Fina Climent, MD PhD, Carmen Aguilera, Mrs, Helena Pomares, MD, Eva González-Barca, MD PhD, Santiago Mercadal, MD, Anna Lucas, MD, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, MD PhD, Octavio Servitje, MD PhD

Blood (2015) 126 (23): 5087.

https://doi.org/10.1182/blood.V126.23.5087.5087

Published: 2015

Journal Articles

Impact of Health Care Funding on Compliance and Survival in Patients with Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Single Institution Experience

Avinash Pasam, MD, Jill Comeau, PharmD, BCOP, Runhua Shi, MDPhDMPH, Srinivas S. Devarakonda, MD

Blood (2015) 126 (23): 5623.

https://doi.org/10.1182/blood.V126.23.5623.5623

Published: 2015

Journal Articles

Short Response Duration to Initial Treatment of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

Deepesh P Lad, MD DM, Subhash Varma, MD, Neelam Varma, MD, Man Updesh Singh Sachdeva, MD, Alka Khadwal, MD, Gaurav Prakash, MD DM, Pankaj Malhotra, MD

Blood (2014) 124 (21): 5665.

https://doi.org/10.1182/blood.V124.21.5665.5665

Published: 2014

Journal Articles

It takes a village

Naomi Winick

Blood (2014) 124 (15): 2316–2317.

https://doi.org/10.1182/blood-2014-05-576900

Published: 2014

Journal Articles

Mercaptopurine Tolerance In Early Treatment and Correlation With Dose Modifications In Maintenance Therapy For Pediatric ALL Patients

Elizabeth D. Alva, MD, Matthew A. Kutny, MD

Blood (2013) 122 (21): 3872.

https://doi.org/10.1182/blood.V122.21.3872.3872

Published: 2013

Journal Articles

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Yehuda E. Deutsch, MD, Daniel J Dammrich, MD, Jesus C Fabregas, MD, Agustin Pimentel, MD, Alexandra Stefanovic, MD, James E. Hoffman, MD

Blood (2013) 122 (21): 5399.

https://doi.org/10.1182/blood.V122.21.5399.5399

Published: 2013

Journal Articles

5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis

Josefina Serrano, Adolfo de la Fuente, MD, Juan Bergua, José Falantes, Martín-Chacón Eusebio, López Juan Antonio, Martinez-Losada MC, Casaño J, Antonio Romero, Prieto Elena, Mendez G, Tabares S, Jose Francisco Tomas, MD, PhD, Sánchez-Garcia Joaquin, Torres Antonio

Blood (2011) 118 (21): 2612.

https://doi.org/10.1182/blood.V118.21.2612.2612

Published: 2011

NARROW

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Plasmablastic Lymphoma - Experience with Infusional EPOCH Chemotherapy from India

Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Cost of Care at NCI-Designated Comprehensive Cancer Centers Vs. Other Treatment Sites for Young Adults with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL)

Real-World Outcomes of Older Patients with Primary Central Nervous System Lymphoma (PCNSL): Methotrexate Dose Intensity and Combination with Cytarabine Correlate with Response and Survival

Influence of Pomalidomide and Lenalidomide on Total Cost of Care for Medicare Beneficiaries with Multiple Myeloma Under the Oncology Care Model (OCM)

Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA)

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Treatment of Primary Cutaneous Marginal Zone B-Cell Lymphomas with Intralesional Rituximab

Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era

Association of Medicare Part D Coverage and Low-Income Subsidies with Use of Novel Oral Agents in Multiple Myeloma

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Impact of Health Care Funding on Compliance and Survival in Patients with Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Single Institution Experience

Short Response Duration to Initial Treatment of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia

It takes a village

Mercaptopurine Tolerance In Early Treatment and Correlation With Dose Modifications In Maintenance Therapy For Pediatric ALL Patients

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only